# Clinical trial results:
# Multicenter, Open-Label, Early Access Program of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Genotype 1 Chronic Hepatitis C Subjects With Severe Fibrosis and Compensated Cirrhosis

## Summary

| | |
|---|---|
| | |
| | |
| | |

### Results information

| | |
|---|---|
| | |
| | |
| | |
| | |

## Trial information

### Trial identification

| | |
|---|---|
| | |

### Additional study identifiers

| | |
|---|---|
| | |
| | |
| | |

### Sponsors

| | |
|---|---|
| | |
| | |
| | |
| | |

### Paediatric regulatory details

| | |
|---|---|
| | |
| | |
| | |

## Results analysis stage

| | |
|---|---|
| | |
| | |
| | |

| |
|---|
| |
| |
| |

## General information about the trial

| |
|---|
| |

| |
|---|
| |
| |

| | |
|---|---|
| | |
| | |
| | |

## Population of trial subjects

## Subjects enrolled per country

| | |
|---|---|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

| Subjects enrolled per age group | |
|---|---|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

## Subject disposition

### Recruitment

### Pre-assignment

### Period 1

| | |
|---|---|
| | |
| | |
| | |
| | |

### Arms

| Arm title | |
|---|---|

| | |
|---|---|
| | |
| | |
| | |
| | |
| | |
| | |

| Number of subjects in period 1 | |
|---|---|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

## Baseline characteristics

| Reporting groups | |
|---|---|
| | |

| Reporting group values | | | |
|---|---|---|---|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

## End points

### End points reporting groups

| | |
|---|---|

| | |
|---|---|
| | |
| | |

| | |
|---|---|
| | |
| | |

| | |
|---|---|
| | |
| | |

| End point values | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| End point values | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |

**Statistical analyses**

| Primary: Percentage of Participants Achieving Sustained Virologic Response (SVR) 24actual (Snapshot, 'less than [<] lower limit of quantification [LLOQ], target not detected') 24 Weeks After the Last Actual Dose of Hepatitis C Virus (HCV) Drug | |
|---|---|
| | |

| | |
|---|---|
| | |

| End point values | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| End point values | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |

**Statistical analyses**

**Primary: Percentage of Participants Achieving Sustained Virologic Response (SVR) 24actual (Classic) 24 Weeks After the Last Actual Dose of Hepatitis C Virus (HCV) Drug**

| | |
|---|---|
| | |

| | |
|---|---|
| | |

| End point values | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| End point values | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |

**Statistical analyses**

**Primary: Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values at Each Time Point During Treatment**

| | |
|---|---|
| | |

| | |
|---|---|
| | |

| End point values | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

**Statistical analyses**

**Primary: Percentage of Participants Achieving Rapid Virologic Response (RVR) at Week 4**

| | |
|---|---|
| | |

| | |
|---|---|
| | |

| End point values | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |

**Statistical analyses**

**Primary: Percentage of Participants Achieving Extended Rapid Virologic Response (eRVR) at Weeks 4 and 12**

| | |
|---|---|
| | |

| | |
|---|---|
| | |

| End point values | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |

**Statistical analyses**

**Primary: Percentage of Participants Having Virologic Response at End of Treatment (Week 24 or 48)**

| | |
|---|---|
| | |

| | |
|---|---|
| | |

| End point values | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| End point values | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

**Statistical analyses**

| Primary: Percentage of Participants With Viral Breakthrough | |
|---|---|
| | |

| | |
|---|---|
| | |

| End point values | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| End point values | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

**Statistical analyses**

**Primary: Percentage of Participants who Relapsed**

| | |
|---|---|
| | |

| | |
|---|---|
| | |

| End point values | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| End point values | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

**Statistical analyses**

**Primary: Percentage of Participants who met a Virologic Stopping Rule**

| | |
|---|---|
| | |

| | |
|---|---|
| | |

| **End point values** | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| **End point values** | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

## Statistical analyses

## Adverse events

| Adverse events information | |
|---|---|
| | |
| **Dictionary used** | |
| | |
| | |
| **Reporting groups** | |
| | |

| Serious adverse events | | | |
|---|---|---|---|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|---|---|---|---|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|---|---|---|---|
| | | | |
| | | | |
| | | | |
| | | | |

| **Non-serious adverse events** | | | |
|---|---|---|---|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|---|---|---|---|
| | | | |
| | | | |

## More information

### Substantial protocol amendments (globally)

| Date | Amendment |
| --- | --- |
| | |
| | |

---

### Interruptions (globally)

### Limitations and caveats